Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allogeneic bone marrow transplantation

I A Tabbara1

  • 1Bone Marrow Transplant Program, George Washington University School of Medicine, Washington, DC 20037, USA.

Southern Medical Journal
|September 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advanced germ cell tumors in male patients.

Southern medical journal·2000
Same author

Empiric antimicrobial therapy of febrile neutropenic patients undergoing haematopoietic stem cell transplantation.

International journal of antimicrobial agents·1999
Same author

Ceftazidime and ciprofloxacin as empiric therapy in febrile neutropenic patients undergoing hematopoietic stem cell transplantation.

Clinical therapeutics·1997
Same author

The role of granulocyte colony-stimulating factor in hematopoietic stem cell transplantation.

Cancer investigation·1997
Same author

The clinical applications of granulocyte colony-stimulating factor in hematopoietic stem cell transplantation: a review.

Anticancer research·1996
Same author

Allogeneic bone marrow transplantation: acute and late complications.

Anticancer research·1996

Allogeneic bone marrow transplantation (BMT) offers a chance for long-term survival for patients with various disorders. Using unrelated donors is increasingly successful when a sibling donor is unavailable.

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Immunology

Background:

  • Allogeneic bone marrow transplantation (BMT) is a primary treatment for hematologic, neoplastic, and congenital disorders.
  • Sibling donors with compatible human leukocyte antigen (HLA) are the most common source for BMT grafts.
  • A significant challenge is that only 30% of patients have an HLA-compatible sibling donor.

Purpose of the Study:

  • To review the established role and evolving use of allogeneic BMT.
  • To highlight the increasing use and outcomes of unrelated donor BMT.
  • To underscore the potential benefits of BMT despite associated risks.

Main Methods:

  • Review of established treatment protocols for allogeneic BMT.
  • Analysis of outcomes using sibling versus unrelated HLA-compatible donors.

Related Experiment Videos

  • Assessment of disease-free survival rates in patients undergoing BMT.

    • Main Results:

    • Allogeneic BMT provides a 20% to 90% chance of long-term, disease-free survival for diverse disorders.
    • Unrelated HLA-compatible donor marrow is being used more frequently with promising results in certain hematologic malignancies.
    • The limited availability of sibling donors necessitates the use of alternative donor sources.

    Conclusions:

    • Allogeneic BMT remains a critical therapeutic option for severe hematologic and neoplastic conditions.
    • The expansion of unrelated donor registries has improved access to BMT for patients lacking sibling donors.
    • Despite significant risks, BMT offers substantial survival benefits for a wide range of patients.